ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RGT Argent Biopharma Limited

27.50
0.00 (0.00%)
08 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Argent Biopharma Limited LSE:RGT London Ordinary Share AU0000326647 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 27.50 26.00 29.00 27.50 27.50 27.50 29,393 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Argent Biopharma Limited Result of Meeting

01/10/2024 10:33am

RNS Regulatory News


RNS Number : 4586G
Argent Biopharma Limited
01 October 2024
 

 

1 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Results of Shareholder's General Meeting

 

Argent BioPharma is pleased to announce the voting results from the Company's General Meeting of Shareholders held today, Tuesday, 1 October 2024.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

 

Details of the results can be found in the following URL:

https://www.investi.com.au/api/announcements/rgt/4ae25edd-f7d.pdf

 

Additionally, the Company advises that it is actively progressing towards the appointment of a sponsor, a key step in moving its listing category from Equity Shares (International Commercial Companies - Secondary Listing) to Equity Shares (Commercial Companies) category (ESCC) of the FCA's Official List. Following the appointment of a sponsor, the Company will be in a position to submit an application to the Financial Conduct Authority (FCA) to facilitate the move between listing categories. Once this process is complete, the Company will provide an updated indicative timetable outlining the anticipated ASX delisting timeline, in accordance with the approval granted by shareholders at the General Meeting held today.

 

There can be no guarantee whether or when an Application to transfer listing category will be approved, notwithstanding the shareholder approval granted today. The Company will not delist from the ASX without such approval of the Application to transfer to the ESCC.

 

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

 

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFZMGGLMZGDZG

1 Year Argent Biopharma Chart

1 Year Argent Biopharma Chart

1 Month Argent Biopharma Chart

1 Month Argent Biopharma Chart

Your Recent History

Delayed Upgrade Clock